Moreover, we demonstrate that these effects of FAP-CAR T cells are sufficient to render tumors permissive to TAA-CAR T cells and endogenous immune cell infiltration and tumoricidal activity, resulting in enhanced anti-tumor activity of Meso-CAR T cells and anti-PD-1 when given in combination with FAP-CAR T cells in our pre-clinical models of PDAC tumors, and as previously reported, a tumor vaccine in combination with FAP-CAR T cells in a more immunogenic mouse model of lung cancer11. The gene discussed is FAP; the disease is neoplasm.